Maintain Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Maintain trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Maintain Trial Today - Breaking & Trending Today

Dr Abdou on Sequencing CDK4/6 Inhibitors in HER2– Metastatic Breast Cancer

Yara Abdou, MD, discusses findings from the phase 2 MAINTAIN trial in patients with HER2-negative metastatic breast cancer, as well as the clinical implications of these trial results. ....

Yara Abdou , Department Of Medicine , University Of North Carolina School Medicine , Division Of Oncology , North Carolina School , Maintain Trial , Patients With Her2 Negative Metastatic Breast Cancer ,

HR+/HER2- Breast Cancer: Inhibiting the PI3K/AKT/mTOR Pathway

Dr Vidal expands on use of PI3K/AKT/mTOR pathway inhibitors following frontline progression, focusing on the PI3K inhibitor alpelisib for patients with PIK3CA mutations, as well as capivasertib, an AKT inhibitor in development. ....

Aditya Bardia , Gregory Vidal , Komal Jhaveri , Hr Her2 Breast Cancer , Cdk4 6 Inhibitors , Second Line Therapies , Endocrine Therapy , Endocrine Resistance , Akt Inhibitors , Capitello 291 , Maintain Trial , Ember 3 , Oral Serds , Viktoria 1 ,

Ribociclib/Fulvestrant Combo Generates PFS Improvement in Metastatic Breast Cancer

Ribociclib plus switch endocrine therapy induced a statistically significant progression-free survival benefit compared with placebo plus switch endocrine therapy in patients with hormone receptor–positive, HER2-negative, metastatic breast cancer. ....

United States , Kevin Kalinsky , Ribociclib Kisqali , Winship Cancer Institute , Emory University , Switch Endocrine Therapy , Maintain Trial , Hormone Receptor Positive Breast Cancer , Her2 Negative Breast Cancer , Breast Cancer , Journal Of Clinical Oncology ,